AIM - Biotech Shares Trading Higher Following Collaborative Research Agreement

A Florida-based %Biotech company captured the attention of the trading community on Tuesday after it was announced that it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca, according to today’s press release.

This news caused shares of %AIMImmunoTech () to get bought up aggressively by traders as the share price reached up to $0.748/share (+19.03%) at the session high. This move is a strong continuation of the success this micro cap has had over the last week.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.